The burgeoning landscape of medication for excess body fat and type 2 metabolic disorder is currently witnessing considerable excitement surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 binding site agonists, significant differences in their pharmacological profiles and clinical study results are emerging.

Retaglutide and tirzepatide represent innovative type of medications known as dual GLP-1 and GIP agonists. These agents influence both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), two hormones that perform a crucial role in regulating blood sugar levels. In individuals with type 2 diabetes, these hormones